Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 11/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449877 | 1.00 | HCRTR2 (0.53) | HCRTR2HCRTR1KMT2AMEN1CMA1 | |
| SCHEMBL7504824 | 1.00 | HCRTR2 (0.53) | HCRTR2HCRTR1KMT2AMEN1CMA1 | |
| SCHEMBL4574022 | 0.92 | HCRTR1 (0.57) | HCRTR2HCRTR1SPHK2 | |
| SCHEMBL4574026 | 0.92 | HCRTR1 (0.57) | HCRTR2HCRTR1SPHK2 | |
| SCHEMBL9634759 | 0.84 | HCRTR2 (0.51) | HCRTR2HCRTR1KMT2AMEN1CMA1 | |
| SCHEMBL20719766 | 0.83 | HCRTR2 (0.55) | HCRTR2HCRTR1KMT2AMEN1CMA1 | |
| SCHEMBL16057511 | 0.83 | KMT2A (0.47) | HCRTR2HCRTR1KMT2ACMA1GAA | |
| SCHEMBL27939968 | 0.83 | HCRTR2 (0.50) | HCRTR2HCRTR1KMT2AMEN1CMA1 | |
| SCHEMBL16088788 | 0.83 | KMT2A (0.47) | HCRTR2HCRTR1KMT2ACMA1GAA | |
| SCHEMBL27939958 | 0.83 | HCRTR2 (0.50) | HCRTR2HCRTR1KMT2AMEN1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317013-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | BILLOT XAVIER (CA) | 2013-11-28 | — | — | US | disclosed |
| EP-1513589-B1 | 1,5-DISUBSTITUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE DISEASES SUCH AS GLAUCOMA | MERCK FROSST CANADA LTD (CA) | 2010-11-10 | — | — | EP | disclosed |
| EP-1513589-B1 | 1,5-DISUBSTITUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE DISEASES SUCH AS GLAUCOMA | MERCK FROSST CANADA LTD (CA) | 2010-11-10 | — | — | EP | disclosed |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | BILLOT XAVIER | 2009-10-15 | — | — | US | disclosed |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | BILLOT XAVIER | 2009-10-15 | — | — | US | disclosed |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | BILLOT XAVIER | 2009-10-15 | — | — | US | disclosed |
| US-20060167081-A1 | Ep4 receptor agonists | MERCK FROSST CANADA LTD. (CA) | 2006-07-27 | — | — | US | disclosed |
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | MERCK FROSST CANADA LTD. (CA) | 2005-10-27 | — | — | US | disclosed |
| EP-1558602-A2 | 2-PYRROLIDONES AS EP4 RECEPTOR AGONISTS | MERCK FROSST CANADA INC. (CA) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004037786-A2 | 2-PYRROLIDONES AS EP4 RECEPTOR AGONISTS | MERCK FROSST CANADA & CO. (CA) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | PTGER1, PTGER4, PTGER2 | HCRTR2 510/4885HCRTR1 1078/4885KMT2A 4294/4885 |
| US-20060167081-A1 | Ep4 receptor agonists | PTGER4, PTGER1, PTGER3 | HCRTR2 270/4885HCRTR1 420/4885KMT2A 2637/4885 |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | HCRTR2 387/4885HCRTR1 563/4885KMT2A 3696/4885 |
| US-20130317013-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | PTGER4, PTGER1, PTGER3 | HCRTR2 387/4885HCRTR1 563/4885KMT2A 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.